semaglutide trevogrumab and garetosmab Regeneron's COURAGE trial shows combo preserves lean mass Are myostatin inhibitors the end

Avcil M, elik A

Safety considerations Researchers are monitoring for: Adverse events Potential safety signals Discontinuation rates Impacts on cardiovascular disease, heart failure, and sleep apnea Changes in blood pressure and HbA1c As with any emerging therapy, more data from Phase 3 trials will be needed to fully understand risk versus benefit

The starting dose of 0.25 mg at this concentration requires just 2.5 units

10.3389/fncel.2019.00585 134 ZhangQ.XiaoX.ZhengJ.LiM.YuM.PingF.et al (2018)

Associated symptoms like persistent muscle cramps, weakness, low blood pressure and anemia can be helped with this supplement